Veri Medtech Holdings Inc.

As of September 30, 2023, Veri Medtech Holdings Inc. carries a market capitalization of 33.36M, placing it among publicly traded companies globally. Its enterprise value stands at 33.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Veri Medtech Holdings Inc. has 55.60M shares outstanding.

These figures are as of September 30, 2023.

As of September 30, 2023, Veri Medtech Holdings Inc. maintains a current ratio of 1,868.46, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

As of the close on September 3, 2026, Veri Medtech Holdings Inc.'s stock has gained approximately 37.93% over the past 52 weeks. The 50-day moving average sits at 4.07, while the 200-day moving average is 2.42.

These figures cover the twelve months ended September 30, 2023.

These figures are as of September 30, 2023. Total book value stands at 155,836.00, with working capital of 44,819.00 providing operational flexibility.

Over the twelve months ended September 30, 2023, Veri Medtech Holdings Inc. posted a gross margin of 88.00, reflecting its pricing power and cost economics. The operating margin of -83.47 and net profit margin of -83.47 provide insight into operational efficiency.

Veri Medtech Holdings Inc.'s most recent stock split took place on September 2, 2026 with a 5:2 split ratio.